Title:
ANTI-CCR8 ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/094003
Kind Code:
A1
Abstract:
The present application relates to the field of biopharmaceuticals, and specifically relates to an antibody specifically binding to CCR8 or an antigen-binding fragment thereof, and a pharmaceutical composition and a kit comprising same. The antibody or the antigen-binding fragment thereof has ADCC activity and/or ADCP activity, and at the same time has a very good tumor inhibitory effect. Therefore, the present invention further relates to use of the antibody or the antigen-binding fragment thereof in the prevention and/or treatment of a tumor.
Inventors:
DAI SHUANG (CN)
ZHAI TIANHANG (CN)
HUANG WEIFENG (CN)
TSUN ANDY (CN)
ZHAI TIANHANG (CN)
HUANG WEIFENG (CN)
TSUN ANDY (CN)
Application Number:
PCT/CN2023/128490
Publication Date:
May 10, 2024
Filing Date:
October 31, 2023
Export Citation:
Assignee:
BIOTHEUS INC (CN)
International Classes:
C07K16/28; A61K39/00; A61P35/00; C12N1/19; C12N1/21
Domestic Patent References:
| WO2022042690A1 | 2022-03-03 | |||
| WO2022081718A1 | 2022-04-21 |
Foreign References:
| CN110835371A | 2020-02-25 | |||
| CN115052892A | 2022-09-13 | |||
| CN114929278A | 2022-08-19 | |||
| CN115087488A | 2022-09-20 |
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: